Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Atara Biotherapeutics ( (ATRA) ) is now available.
On October 6, 2025, Atara Biotherapeutics announced a workforce reduction affecting about 29% of its employees, with the aim of aligning its operations with strategic priorities. The company anticipates incurring approximately $1.3 million in severance and related benefits, with completion expected by January 2026, and further financial details to be disclosed in their upcoming quarterly report.
The most recent analyst rating on (ATRA) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.
Spark’s Take on ATRA Stock
According to Spark, TipRanks’ AI Analyst, ATRA is a Neutral.
Atara Biotherapeutics’ overall stock score is primarily impacted by its financial instability, with negative equity and cash flow issues being significant concerns. The technical analysis provides some positive momentum, but valuation metrics are weak due to negative earnings. The absence of earnings call and corporate events data limits further insights.
To see Spark’s full report on ATRA stock, click here.
More about Atara Biotherapeutics
Atara Biotherapeutics is a company in the biotechnology industry, focusing on developing therapies for patients with serious diseases. The company is known for its work in immunotherapy, particularly in the development of allogeneic T-cell therapies.
Average Trading Volume: 56,886
Technical Sentiment Signal: Buy
Current Market Cap: $98.18M
See more data about ATRA stock on TipRanks’ Stock Analysis page.